** Patients will be followed until PSA reaches baseline. Patients who continue to be followed for rising PSA but have not requi red ADT may be seen beyond the study period. The study period ends 52 weeks after enrollme nt unless patients rece ive a second course of enzalutamide, then study period ends 9 m onths after the end of the second course. 1As indicated in section 7.3, all subjects will be offered th e opportunity to complete an NIH advanced directives form. This should be done preferably at baseline but can be done at any time during the study as long as the capacity to do so is retained.